Amanote Research
Register
Sign In
Mixed Reviews for A2AR Inhibitor in NSCLC
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2018-157
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
November 29, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
P1.04-32 Phase I/Ii Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (Pts) With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
P3.04-14 TMB and Immune Checkpoint Inhibitor Gene Expression Are Unrelated in NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Mixed Reviews on Removing Fallopian Tubes to Prevent Ovarian Cancer
CMAJ
Medicine
P3.01-55 SF2: A PCYT-2 Inhibitor Prototype Is Capable of Inducing Citotoxicity in NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.13-05 Integrin Β3 Inhibition Enhances the Antitumor Activity of Alk Inhibitor in Alkrearranged NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Looking for the Best Immune-Checkpoint Inhibitor in Pre-Treated NSCLC Patients: An Indirect Comparison Between Nivolumab, Pembrolizumab and Atezolizumab
International Journal of Cancer
Cancer Research
Oncology
